NCT06624878View on ClinicalTrials.gov

Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

NARecruitingINTERVENTIONAL
Enrollment

568

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Ovarian CancerCytoreductive SurgeryDepressive Symptom
Interventions
DRUG

esketamine

0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.

DRUG

placebo

a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.

Trial Locations (1)

310022

RECRUITING

Zhejiang cancer hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER